

Chemoselective C-Terminal Activation Platform for Direct Conversion of Native Linear Peptides into Thiazoline/Thiazole Macrocycles

Bao Quang Gia Le, Minyoung Kwon, and Monika Raj*

Cite This: <https://doi.org/10.1021/acs.orglett.6c01073>

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information


ABSTRACT: We report a sequence-independent, chemoselective C-terminal activation platform to synthesize thiazoline/thiazole macrocycles from native linear peptides. Selective C-terminal primary amide-to-nitrile conversion proceeds in solution on fully unprotected peptides with broad functional-group compatibility. This approach eliminates the need for presynthesized α -amino nitrile building blocks and minimizes epimerization risk. Our method enables rapid macrocyclization, supporting the direct total syntheses of Mollamide F, Sanguinamide A, and Haligramide A from linear precursors.



Introduction

Macrocyclic peptides are an important modality for accessing targets that are challenging for small molecules while retaining greater structural tunability than biologics.^{1–5} In many bioactive marine macrocycles, such as Mollamide F,

A. Previous work



B. This work




Figure 1. (A) Previous work requires multistep synthesis of individual amino acid nitriles and limited to C-terminal hydrophobic amino acids. (B) This work: Chemoselective C-terminal activation of C-terminal amide peptide to C-terminal nitrile peptide independent of the amino acid and their one pot cyclization to thiazoline cyclic peptide via N-terminal Cys-nitrile cyclization.

Sanguinamide A, and Haligramide A, thiazoline and thiazole heterocycles are embedded directly within the peptide backbone.^{6,7} Unlike external staples or side chain cyclizations, these backbone-embedded heterocycles drastically reduce conformational flexibility and mask polar amide bonds, thereby unlocking unique physical properties such as enhanced membrane permeability and proteolytic stability.^{8–12}

Despite their value, accessing native thiazoline/thiazole backbone topologies remains challenging. Classical approaches rely on preinstalled heterocyclic building blocks during peptide assembly or on postsynthetic cyclodehydration conditions that can be harsh, low-yielding, and substrate-dependent.^{13–16} More recently, biocompatible N-terminal cysteine condensation with C-terminal nitriles has enabled thiazoline formation (and, upon oxidation, thiazoles), but these strategies typically require specialized synthesis of chiral α -amino nitrile precursors prior to peptide assembly (Figure 1A).^{17,18} Current methods are limited to the synthesis of hydrophobic amino acid nitriles without any reactive group on the side chain.¹⁸ This added synthesis slows library generation and may introduce epimerization risk, particularly when expanding to amino acids containing reactive side chains.¹⁸

Received: March 9, 2026

Revised: April 3, 2026

Accepted: April 14, 2026




Figure 2. Peptide scope of converting backbone amide to backbone nitrile independent of amino acid at the C-terminus and the use of DTT for removing palladium from the reaction mixture.

Here we report a late-stage, sequence-tolerant C-terminal activation strategy that converts fully assembled, unprotected peptides into thiazoline/thiazole macrocycles (Figure 1B). Using palladium(II) trifluoroacetate (Pd(TFA)_2), we selectively dehydrate the C-terminal primary amide of native peptides to the corresponding nitrile at room temperature with high chemoselectivity, leaving common side-chain functional groups intact. Because the transformation is performed on completed peptides, stereochemical integrity is preserved without reliance on α -amino nitrile building blocks. We demonstrate rapid access to thiazoline/thiazole-containing macrocycles across 5–9 amino-acid ring sizes with 95–99% conversion and apply the platform to the total syntheses of Mollamide F, Haligramide A, and Sanguinamide A directly from their linear amide precursors. Consequently, this study establishes a universal platform for the construction of thiazoline and thiazole macrocycles, offering unrestricted access to bioactive peptide architectures.

Results and Discussion

Development of a Chemoselective C-Terminal Activation Platform. To establish a sequence-tolerant route to thiazoline/thiazole macrocycles, we first optimized the C-

terminal activation sequence using a dipeptide model. Traditional methods for dehydrating primary amides to nitriles are often complicated by the presence of other nucleophilic or protic functional groups, presenting a significant challenge for complex biomolecules.^{19,20} To overcome this limitation, we drew inspiration from recent advances in palladium-catalyzed amide dehydrations, which are renowned for their exceptional chemoselectivity and ability to proceed under mild conditions. Thus, using Pd(TFA)_2 in acetonitrile enabled us to perform direct dehydration of the C-terminal primary amide to the corresponding nitrile on a dipeptide at room temperature as characterized by NMR and HRMS (Figure S1). This late-stage activation avoids external nitrile reagents and eliminates the need for presynthesized α -amino nitrile building blocks.¹⁸ The resulting nitrile dipeptide was screened for optimal condensation conditions with L-cysteine methyl ester hydrochloride by varying temperature, solvents, bases and amounts of IPA:PBS (pH 7.4) with N,N-diisopropylethylamine (DIPEA) facilitated the formation of thiazoline dipeptide in 95% conversion (Table S1). While DIPEA was necessary to neutralize the hydrochloride salt during this intermolecular step, we later observed that subsequent intramolecular cyclizations proceeded efficiently without additional base. Notably, during purification, we found that thiazolines are acid-labile and can hydrolyze under standard reverse-phase conditions containing acidic additives (e.g., 0.1% formic acid). Using acid-free purification protocols, thiazoline dipeptide was successfully isolated and characterized by NMR and HRMS (Figure S2).

Downstream Reactivity: Hydrolysis and Thiazole Formation. With thiazoline dipeptide in hand, we examined its conversion to additional motifs. Exposure of thiazoline dipeptide to formic acid provided rapid hydrolysis to the corresponding native backbone peptide (Cys at the cyclization site) in 96% conversion as characterized by NMR and HRMS (Figure S3). To optimize thiazole formation, we screened a variety of reaction conditions, including different oxidants and oxidant loadings (Table S2). Literature-reported oxidation conditions employing MnO_2 at 80 °C were ineffective for the purified dipeptide.²¹ Notably, inclusion of K_2CO_3 substantially enhanced the reaction rate, and systematic evaluation showed that K_2CO_3 alone or in combination with MnO_2 at 80 °C was sufficient to furnish the thiazole dipeptide in $>99\%$ conversion, as confirmed by NMR and HRMS (Table S2, Figure S4).²²

Chemoselectivity and Cyclization Selectivity. After optimizing the dehydration protocol, we evaluated functional-group compatibility using peptide YWRMCKEHS, which contains a broad set of potentially reactive side chains. Treatment with Pd(TFA)_2 in acetonitrile at room temperature produced no detectable side-chain modifications by LC-MS, consistent with preferential reactivity toward peptide primary amide functionalities under these conditions (Figure S5).

Because Pd(TFA)_2 can also dehydrate asparagine/glutamine side-chain amides to the corresponding nitriles, we next asked whether an aliphatic side-chain nitrile could compete with the intended C-terminal nitrile in N-terminal cysteine cyclization. Two peptides with closely related sequences were prepared: peptide CWPAYA bearing a C-terminal primary amide, and peptide CWPAYQ bearing a C-terminal carboxylic acid and a glutamine residue. Exposure of each peptide to Pd(TFA)_2 in acetonitrile at room temperature afforded the corresponding nitrile products: a C-terminal backbone nitrile (CWPAYA-




Figure 3. Peptide scope for the cyclization of backbone nitriles to thiazoline peptides and subsequent modification to thiazole peptides. Conversions to thiazoline and thiazole cyclic peptides are independent of peptide sequence and ring size.

Nitrile) and a side-chain nitrile (CWPAYQ-Nitrile-COOH) (Figures S6 and S7).

Notably, during initial cyclization attempts, we observed poor thiazoline formation, consistent with palladium coordination to the peptide (including the N-terminal cysteine) that inhibits productive condensation. Addition of dithiothreitol (DTT) effectively scavenged palladium, forming an insoluble Pd-thiol complex that was removed by filtration to afford nitrile peptides suitable for cyclization (Figure 2). Upon solvent removal, both nitrile peptides were subjected to cyclization in IPA:PBS (pH 7.4). After stirring at room temperature, only the peptide bearing the C-terminal nitrile cyclized to give CWPAYA-thiazoline (Figure S6). In contrast, the peptide bearing a side-chain nitrile formed a cysteine disulfide dimer with no detectable thiazoline (Figure S7). These results demonstrate that thiazoline formation occurs selectively between N-terminal cysteine and the C-terminal nitrile, rather than aliphatic side-chain nitriles, enabling construction of backbone-embedded thiazoline macrocycles with native topology with high selectivity even in the presence of glutamine and asparagine.

Furthermore, the side-chain nitrile is reversible; treatment of peptide, WGNFL with Pd(TFA)₂ in acetonitrile converted the asparagine residue to its nitrile form, and subsequent exposure of the purified WGN-Nitrile-FL-COOH to Pd(TFA)₂ with

acetamide in THF:H₂O or IPA:H₂O (1:1) at room temperature restored the asparagine native amide structure (Figure S8).

Substrate Scope and Diversification to Varying Cyclic Peptides. We next applied the protocol to six peptides varying in sequence, C-terminal residue, and ring size, each bearing an N-terminal cysteine and prepared by SPPS on Rink resin (Figure 2). Pd(TFA)₂-mediated dehydration afforded the corresponding nitrile peptides **1b–6b** in high conversion (Figures S9–S14). Furthermore, to assess the robustness of the Pd(TFA)₂-mediated dehydration method with respect to the C-terminal amino acid, we also prepared C-terminal nitrile peptides containing diverse and potentially reactive C-terminal residues, including Cys, Arg, Trp, His, Ser, Tyr, Lys, Glu, and Met, achieving conversions of 47–99% (Table S3). Following palladium scavenging and solvent evaporation, the crude peptide nitriles (**1b–6b**) were directly subjected to cyclization in IPA:PBS (pH 7.4), providing thiazoline macrocycles **1c–6c** in similarly high conversion. This series included Mollamide F (**1c**), an anti-HIV macrocycle isolated from *Didemnum molle*, and **6c**, a structural analog of Phakellistatin 13 in which a native 5-membered proline ring is replaced with a thiazoline core (Figure 3).

The cyclization kinetics were notably dependent on the C-terminal residue. While most analogs (**1b**, **3b–6b**) cyclized at




Figure 4. Peptide scope for the synthesis of native cyclic peptides from hydrolysis of thiazoline peptides. Full conversion to native cyclic peptides was observed independent of peptide sequence and ring size.

room temperature, the sterically hindered isoleucine derivative **2b** required heating (70 °C) for full conversion (Figure S10). In contrast, replacing the isoleucine with the less sterically hindered alanine (**3b**) restored room-temperature reactivity (Figure S11), highlighting the impact of steric congestion on the cyclization rate. To further demonstrate the robustness of cyclization with respect to C-terminal amino acids, we prepared additional thiazoline peptides bearing bulky, charged, and potentially reactive C-terminal residues, including Trp, Glu, Arg, and Met, all of which cyclized in 95–99% conversion (Table S4).

Next, we applied the optimized reaction conditions to convert thiazoline cyclic peptides to the corresponding thiazole macrocycles. Treatment with MnO₂/K₂CO₃ delivered thiazoles **1d–3d** and **5d** in quantitative conversion, including Sanguinamide A (**2d**) and Haligramide A (**5d**) (Figure 3, Figures S15–S20). Notably, peptide **5c** bears two Met residues that could be susceptible to oxidation, yet thiazoline **5c** was cleanly converted to Haligramide A (**5d**) in quantitative yield without any Met oxidation.

In contrast, oxidation of thiazolines **4c** and **6c** initially produced no detectable thiazole products. We hypothesized that the His residue in (**4c**) and the Trp residue in (**6c**) interact with MnO₂, resulting in product loss during filtration.

In support of this hypothesis, use of K₂CO₃ alone, without MnO₂, enabled formation of thiazoles **4d** and **6d** in high conversion (Figure 3). Finally, the thiazoline cyclic peptides were converted to the native cyclic peptides by treatment with formic acid, regenerating macrocycles **1e–6e** bearing a native amide backbone and Cys at the cyclization site (Figure 4, Figures S21–S26).

Conclusion

We report a chemoselective C-terminal activation platform that converts native, fully unprotected linear peptides into thiazoline/thiazole macrocycles through late-stage C-terminal amide-to-nitrile dehydration using Pd(TFA)₂ under mild, solution-phase conditions. Palladium scavenging with DTT enables efficient N-terminal Cys cyclization, and chemoselectivity studies show that thiazoline formation occurs exclusively with a C-terminal backbone nitrile, while Asn/Gln-derived side-chain nitriles do not compete. The method is broadly compatible across sequences and ring sizes, delivers near-quantitative nitrile formation and high-conversion to thiazoline macrocycles, and supports downstream diversification to thiazole macrocycles or hydrolyzed native-backbone macrocycles. This streamlined approach eliminates specialized α -amino nitrile building blocks and provides rapid access to backbone-embedded heterocycles, enabling direct total syntheses of bioactive cyclic peptides, Mollamide F, Sanguinamide A, and Haligramide A directly from their linear precursors.

ASSOCIATED CONTENT

Data Availability Statement

The data underlying this study are available in the published article and its Supporting Information.

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.orglett.6c01073>.

General experimental procedures and characterization details, including HPLC, HRMS, and ¹H and ¹³C NMR spectra of all reported compounds (PDF)

AUTHOR INFORMATION

Corresponding Author

Monika Raj – Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States; orcid.org/0000-0001-9636-2222; Email: monika.raj@emory.edu

Authors

Bao Quang Gia Le – Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States; orcid.org/0000-0003-3311-2706

Minyoung Kwon – Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acs.orglett.6c01073>

Author Contributions

Bao Quang Gia Le, Minyoung Kwon, and Monika Raj designed the study. Bao Quang Gia Le and Minyoung Kwon performed all the experiments and characterization. Bao Quang Gia Le and Monika Raj wrote the manuscript. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This research was supported by NIH (Grant No. 1R01HG012941-01) and NSF (Grant No. CHE-2406996) to M.R. All figures were created with biorender.com.

REFERENCES

- (1) Blanco, M.-J.; Gardinier, K. M. New chemical modalities and strategic thinking in early drug discovery. *ACS Med. Chem. Lett.* **2020**, *11*, 228–231.
- (2) Colas, K.; Bindl, D.; Suga, H. Selection of nucleotide-encoded mass libraries of macrocyclic peptides for inaccessible drug targets. *Chem. Rev.* **2024**, *124*, 12213–12241.
- (3) Dougherty, P. G.; Qian, Z.; Pei, D. Macrocycles as protein–protein interaction inhibitors. *Biochem. J.* **2017**, *474*, 1109–1125.
- (4) Dougherty, P. G.; Sahni, A.; Pei, D. Understanding cell penetration of cyclic peptides. *Chem. Rev.* **2019**, *119*, 10241–10287.
- (5) Garcia Jimenez, D.; Poongavanam, V.; Kihlberg, J. Macrocycles in drug discovery—Learning from the past for the future. *J. Med. Chem.* **2023**, *66*, 5377–5396.
- (6) Li, Y.; Li, W.; Xu, Z. Improvement on Permeability of Cyclic Peptide/Peptidomimetic: Backbone N-Methylation as A Useful Tool. *Mar. Drugs* **2021**, *19*, 311.
- (7) Dahiya, R.; Dahiya, S.; Fuloria, N. K.; Kumar, S.; Mourya, R.; Chennupati, S. V.; Jankie, S.; Gautam, H.; Singh, S.; Karan, S. K.; Maharaj, S.; Fuloria, S.; Shrivastava, J.; Agarwal, A.; Singh, S.; Kishor, A.; Jadon, G.; Sharma, A. Natural Bioactive Thiazole-Based Peptides from Marine Resources: Structural and Pharmacological Aspects. *Mar. Drugs* **2020**, *18*, 329.
- (8) Smolyar, I. V.; Yudin, A. K.; Nenajdenko, V. G. Heteroaryl Rings in Peptide Macrocycles. *Chem. Rev.* **2019**, *119*, 10032–10240.
- (9) Bockus, A. T.; Schwochert, J. A.; Pye, C. R.; Townsend, C. E.; Sok, V.; Bednarek, M. A.; Lokey, R. S. Going Out on a Limb: Delineating the Effects of β -Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. *J. Med. Chem.* **2015**, *58*, 7409–7418.
- (10) Agouram, N.; El Hadrami, E. M.; Bentama, A. 1,2,3-Triazoles as biomimetics in peptide science. *Molecules* **2021**, *26*, 2937.
- (11) Kumari, S.; Carmona, A. V.; Tiwari, A. K.; Trippier, P. C. Amide bond bioisosteres: Strategies, synthesis, and successes. *J. Med. Chem.* **2020**, *63*, 12290–12358.
- (12) Mak, J. Y. W.; Xu, W.; Fairlie, D. P. Thiazoles in peptides and peptidomimetics. *Top. Heterocycl. Chem.* **2015**, *48*, 235–266.
- (13) Kumar, S.; Arora, A.; Sapra, S.; Kumar, R.; Singh, B. K.; Singh, S. K. Recent Advances in the Synthesis and Utility of Thiazoline and Its Derivatives. *RSC Adv.* **2024**, *14*, 902–953.
- (14) Hamdan, F.; Tahoori, F.; Balalaie, S. Synthesis of Novel Cyclopeptides Containing Heterocyclic Skeletons. *RSC Adv.* **2018**, *8*, 33893–33926.
- (15) Nielsen, D. S.; Hoang, H. N.; Lohman, R.-J.; Diness, F.; Fairlie, D. P. Total Synthesis, Structure, and Oral Absorption of a Thiazole Cyclic Peptide, Sanguinamide A. *Org. Lett.* **2012**, *14*, 5720–5723.
- (16) Koch, L.; Wiedemann, C.; Parthier, C.; Seidel, R. W.; Stubbs, M. T.; Schutkowski, M.; Meleshin, M. Total Synthesis and Structural Revision of Keenamamide A. *J. Nat. Prod.* **2026**, *89*, 483–491.
- (17) He, J.; Nitsche, C. Biocompatible synthesis of macrocyclic thiazol(in)e peptides. *Chem.—Eur. J.* **2024**, *30*, No. e202401716.
- (18) Shang, M.; He, J.; Gardiner, M. G.; Nitsche, C. Biocompatible Synthesis of Macrocyclic Thiazole Peptides from Chiral α -Amino Nitriles. *Org. Biomol. Chem.* **2025**, *23*, 9815–9818.
- (19) Rickborn, B.; Jensen, F. R. α -Carbon Isomerization in Amide Dehydrations. *J. Org. Chem.* **1962**, *27*, 4608–4610.
- (20) Ellzey, S. E., Jr.; Mack, C. H.; Connick, W. J., Jr. Dehydration of primary amides with sodium borohydride. *J. Org. Chem.* **1967**, *32*, 846–847.
- (21) Yu, Y.-B.; Chen, H.-L.; Wang, L.-Y.; Chen, X.-Z.; Fu, B. A Facile Synthesis of 2,4-Disubstituted Thiazoles Using MnO₂. *Molecules* **2009**, *14*, 4858–4865.
- (22) Huang, Y.; Gan, H.; Li, S.; Xu, J.; Wu, X.; Yao, H. Oxidation of 4-Carboxylate Thiazolines to 4-Carboxylate Thiazoles by Molecular Oxygen. *Tetrahedron Lett.* **2010**, *51*, 1751–1753.